DE69535407D1 - Verfahren zur induzierung von genexpression mittels ionisierender strahlung - Google Patents

Verfahren zur induzierung von genexpression mittels ionisierender strahlung

Info

Publication number
DE69535407D1
DE69535407D1 DE69535407T DE69535407T DE69535407D1 DE 69535407 D1 DE69535407 D1 DE 69535407D1 DE 69535407 T DE69535407 T DE 69535407T DE 69535407 T DE69535407 T DE 69535407T DE 69535407 D1 DE69535407 D1 DE 69535407D1
Authority
DE
Germany
Prior art keywords
ionizing radiation
gene expression
inducing gene
radiation
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69535407T
Other languages
English (en)
Other versions
DE69535407T2 (de
Inventor
Tsuneya Ohno
Ralph R Wiechselbaum
Donald W Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
University of Chicago
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Dana Farber Cancer Institute Inc filed Critical University of Chicago
Publication of DE69535407D1 publication Critical patent/DE69535407D1/de
Application granted granted Critical
Publication of DE69535407T2 publication Critical patent/DE69535407T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
DE69535407T 1994-05-11 1995-05-11 Verfahren zur induzierung von genexpression mittels ionisierender strahlung Expired - Fee Related DE69535407T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/241,863 US5571797A (en) 1994-05-11 1994-05-11 Method of inducing gene expression by ionizing radiation
US241863 1994-05-11
PCT/US1995/005959 WO1995031559A2 (en) 1994-05-11 1995-05-11 Methods of inducing gene expression by ionizing radiation

Publications (2)

Publication Number Publication Date
DE69535407D1 true DE69535407D1 (de) 2007-04-12
DE69535407T2 DE69535407T2 (de) 2007-11-29

Family

ID=22912470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535407T Expired - Fee Related DE69535407T2 (de) 1994-05-11 1995-05-11 Verfahren zur induzierung von genexpression mittels ionisierender strahlung

Country Status (6)

Country Link
US (1) US5571797A (de)
EP (1) EP0759083B1 (de)
AT (1) ATE355381T1 (de)
AU (1) AU696210B2 (de)
DE (1) DE69535407T2 (de)
WO (1) WO1995031559A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
CA2098849C (en) * 1990-12-20 2007-07-10 Ralph R. Weichselbaum Control of gene expression by ionizing radiation
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5641754A (en) * 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
AU4994596A (en) * 1995-03-01 1996-09-18 Cornell Research Foundation Inc. Interdependent adenoviral vectors and methods of using same
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
ATE345682T1 (de) 1996-05-01 2006-12-15 Imarx Pharmaceutical Corp In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
DE69736692T2 (de) * 1996-07-16 2007-06-14 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5948681A (en) * 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
DE69737915T2 (de) 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators
CA2283108A1 (en) * 1997-03-10 1998-09-17 Research Development Foundation Photodynamic therapy generated oxidative stress for temporal and selective expression of heterologous genes
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6025365A (en) * 1997-03-25 2000-02-15 Arch Development Corp. Chelerythrine and radiation combined tumor therapy
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
AU1390699A (en) * 1997-11-17 1999-06-07 Imarx Pharmaceutical Corp. A method of increasing nucleic acid synthesis with ultrasound
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6841538B1 (en) * 1998-04-22 2005-01-11 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and radio therapy
US6841537B1 (en) 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
WO2002049501A2 (en) * 2000-12-18 2002-06-27 Board Of Regents, University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
EP1390075B1 (de) * 2001-04-06 2012-01-18 The University of Chicago Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie
US8034791B2 (en) * 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20050171396A1 (en) * 2003-10-20 2005-08-04 Cyberheart, Inc. Method for non-invasive lung treatment
WO2005051432A1 (en) * 2003-11-14 2005-06-09 Genvec, Inc. Therapeutic regimen for treating cancer
CA2577550C (en) * 2004-08-25 2012-10-16 The University Of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
US20060234272A1 (en) * 2005-03-31 2006-10-19 The Regents Of The University Of California Using gene panels to predict tissue sensitivity to ionizing radiation
US20080076122A1 (en) * 2006-09-26 2008-03-27 The Regents Of The University Of California Characterizing exposure to ionizing radiation
DE102008048036A1 (de) * 2008-09-19 2010-03-25 Meurer, Heinrich, Dr. Verfahren zur Detektion ionisierender Strahlung
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
TW201204426A (en) 2010-02-12 2012-02-01 Todd F Ovokaitys A laser enhanced amino acid blend and use of same to regenerate active myocardial tissue
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
EP4127186A1 (de) 2020-03-24 2023-02-08 Generation Bio Co. Nichtvirale dna-vektoren und verwendungen davon zur expression von gaucher-therapeutika
US20230138409A1 (en) 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392300B1 (de) * 1989-04-11 1992-08-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verwendung von mindestens ein Cytokin zur Herstellung eines Arzneimittels zur systemischen Behandlung von präneoplastischen Läsionen
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions

Also Published As

Publication number Publication date
US5571797A (en) 1996-11-05
EP0759083B1 (de) 2007-02-28
AU696210B2 (en) 1998-09-03
EP0759083A1 (de) 1997-02-26
ATE355381T1 (de) 2006-03-15
WO1995031559A3 (en) 1996-01-11
WO1995031559A2 (en) 1995-11-23
AU2689195A (en) 1995-12-05
DE69535407T2 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DE69535407D1 (de) Verfahren zur induzierung von genexpression mittels ionisierender strahlung
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
Platz et al. Tissue specificity of non-histone chromatin phosphoproteins
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE3587939D1 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
ATE119915T1 (de) Dns-sequenzen, rekombinante dns-moleküle und verfahren zur herstellung von ''mullerian inhibiting substance''-ähnlichen polypeptiden.
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
ATE314482T1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
DE69233478D1 (de) Neue menschliche cdc25 gene, kodierte produkte und ihre verwendung
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
DE69002325D1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
ATE389023T1 (de) Kontrolle der schotendehiszenz
FI970735A0 (fi) Menetelmät autoimmuunisairauksien käsittelyyn käyttökelpoisten yhdisteiden identifioimiseksi
AU2932100A (en) Neurodegenerative disorder related gene
CA2192813A1 (en) Methods of inducing gene expression by ionizing radiation
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
ES2117717T3 (es) Tratamiento de tumores con factores neurotroficos e inhibidores de la proliferacion celular.
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
ATE340260T1 (de) Verfahren zur behandlung von tumoren mittels antiangiogener substanzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee